We are live on ! Find out more
CYCN icon

Cyclerion Therapeutics
CYCN

37 hedge funds and large institutions have $18.3M invested in Cyclerion Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more capital invested

Capital invested by funds: $11.5M → $18.3M (+$6.79M)

0.04% more ownership

Funds ownership: 2.41% → 2.44% (+0.04%)

10% less funds holding

Funds holding: 41 → 37 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

71% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 14

Holders
37
Holders Change
-4
Holders Change %
-9.76%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
14
Closed
6
Calls
$401K
Puts
–
Net Calls
+$401K
Net Calls Change
+$147K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$753K
2
Citadel Advisors
Citadel Advisors
Florida
+$9.16K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.7K
4
Franklin Resources
Franklin Resources
California
+$791
5
GAG
Goodman Advisory Group
Massachusetts
+$309

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$148K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$88.9K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$51.6K
4
Jane Street
Jane Street
New York
-$32K
5
TSS
Two Sigma Securities
New York
-$29.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$6.16M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.94M +$753K +43,807 +35%
MP
3
MFN Partners
Massachusetts
$2.92M – – –
AG
4
Artal Group
Luxembourg
$2.39M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.42M -$88.9K -5,173 -6%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$502K +$8.7K +506 +2%
BlackRock
7
BlackRock
New York
$310K -$773 -45 -0.2%
TFS
8
TrustCore Financial Services
Tennessee
$252K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$244K -$148K -8,635 -38%
DC
10
Diametric Capital
Massachusetts
$210K +$155 +9 +0.1%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$198K – – –
BCM
12
Bridgeway Capital Management
Texas
$99K – – –
State Street
13
State Street
Massachusetts
$99K – – –
CG
14
Colony Group
Massachusetts
$88K – – –
PCM
15
Prelude Capital Management
New York
$80K -$28.9K -1,683 -27%
Northern Trust
16
Northern Trust
Illinois
$69K – – –
Franklin Resources
17
Franklin Resources
California
$68K +$791 +46 +1%
IVP
18
Intrinsic Value Partners
Arizona
$42K – – –
Millennium Management
19
Millennium Management
New York
$39K -$5.36K -312 -12%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$31K -$51.6K -3,005 -62%
Mackenzie Financial
21
Mackenzie Financial
Ontario, Canada
$23K -$11.7K -680 -33%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$23K -$4.43K -258 -16%
TSS
23
Two Sigma Securities
New York
$17K -$29.6K -1,720 -63%
Verition Fund Management
24
Verition Fund Management
Connecticut
$17K – – –
Group One Trading
25
Group One Trading
Illinois
$15K -$344 -20 -2%
1
2

CYCN Hedge Fund Activity: Q3 2022 in Review

37 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2022, worth a combined $18.3M — up 59% from $11.5M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CYCN and 2 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.

The largest buyer was Fidelity Investments, adding an estimated $753K. The largest seller was Renaissance Technologies, cutting an estimated $148K.

  • 37 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2022, down from 41 in Q2 2022.
  • Funds reported $18.3M of Cyclerion Therapeutics stock for Q3 2022, up 59% quarter-over-quarter.
  • 2 funds opened new Cyclerion Therapeutics positions in Q3 2022 and 6 closed out, a net change of -4 holders.
  • The largest Cyclerion Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $753K added.
  • The largest Cyclerion Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $148K sold.

Based on aggregated 13F filings for Q3 2022.